Not available
Quote | Arcus Biosciences Inc. (NYSE:RCUS)
Last: | $14.13 |
---|---|
Change Percent: | -1.05% |
Open: | $14.39 |
Close: | $14.28 |
High: | $14.495 |
Low: | $14.01 |
Volume: | 248,340 |
Last Trade Date Time: | 07/22/2024 03:00:00 am |
News | Arcus Biosciences Inc. (NYSE:RCUS)
Arcus Biosciences, Inc. (NYSE:RCUS) and Taiho Pharmaceutical Co., Ltd. (“Taiho”) today announced that Taiho exercised its option for quemliclustat (International Nonproprietary Name; development code: AB680), an investigational small molecule CD73 inhibitor, in Japan and certain oth...
2024-07-05 07:18:27 ET More on Roche Roche: Obesity Treatment's Promise Isn't Enough More Of The Same Isn't Good Enough For Roche Roche Is Joining The Obesity Party But Questions Remain Roche's crovalimab wins FDA approval for paroxysmal nocturnal hemoglobinu...
Message Board Posts | Arcus Biosciences Inc. (NYSE:RCUS)
Subject | By | Source | When |
---|---|---|---|
Biotechs are starting to react to news...finally. | conix | investorshub | 04/05/2022 3:26:51 PM |
The stock didn't react as well as expected | dinogreeves | investorshub | 05/27/2020 12:46:59 PM |
Also in the DEF 14.....didnt see any information | lovetc | investorshub | 04/22/2020 2:48:12 AM |
shorted some and bought some put at $31 | lovetc | investorshub | 04/22/2020 2:46:30 AM |
RCUS will likely hit 40 this week and | dinogreeves | investorshub | 04/21/2020 1:25:35 AM |
News, Short Squeeze, Breakout and More Instantly...
Arcus Biosciences Inc. Company Name:
RCUS Stock Symbol:
NYSE Market:
Arcus Biosciences Inc. Website:
Arcus Biosciences, Inc. (NYSE:RCUS) and Taiho Pharmaceutical Co., Ltd. (“Taiho”) today announced that Taiho exercised its option for quemliclustat (International Nonproprietary Name; development code: AB680), an investigational small molecule CD73 inhibitor, in Japan and certain oth...
Domvanalimab is the only anti-TIGIT antibody in Phase 3 for upper gastrointestinal (GI) adenocarcinomas with the potential to be first-to-market for this patient population Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing di...
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a fireside chat at the upcoming Goldman Sachs 45 th Annual ...